News
Sementis’ quest for an Australian second-generation COVID-19 vaccine
October 2021 A South Australian start-up biotech company, Sementis Limited, has joined the global quest to develop a...
November 2018
Australian biotechnology firm Sementis has entered into a research and development (R&D) partnership with UK-based Enesi Pharma for the development of potential vaccine candidates to treat peanut allergy and chikungunya/Zika infection.
Read more in Pharmaceutical Technology here.
News
October 2021 A South Australian start-up biotech company, Sementis Limited, has joined the global quest to develop a...
News
September 2021 Researchers in Australia have developed a coronavirus disease 2019 (COVID-9) vaccine that induced robust...
News
August 2021 Adelaide biotech company Sementis is aiming to raise $10m to accelerate work on its next-generation Covid-19...